Markers of acute myeloid leukemia stem cells
View Patent ↗Markers of acute myeloid leukemia stem cells (AMLSC) are identified. The markers are differentially expressed in comparison with normal counterpart cells, and are useful as diagnostic and therapeutic targets.
1. A method of targeting or depleting acute myeloid leukemia cancer stem cells (AMLSC), the method comprising:
contacting blood cells of a human suffering from acute myeloid leukemia with an antibody that specifically binds CD99 in order to target or deplete AMLSC.
2. The method of claim 1 , wherein the antibody is a bispecific antibody that binds CD99 and a marker set forth in Table 1.
3. The method of claim 1 , wherein the antibody is conjugated to a cytotoxic agent.
4. The method of claim 3 , wherein said cytotoxic agent is selected from the group consisting of a radioactive isotope, a chemotherapeutic agent and a toxin.
5. The method of claim 1 , wherein the contacting depletes the blood cells of AMLSC.
6. The method of claim 1 , wherein the contacting is in vivo.
7. A method of targeting or depleting acute myeloid leukemia cancer stem cells (AMLSC), the method comprising:
contacting blood cells of a human suffering from acute myeloid leukemia with an antibody that specifically binds TIM3 in order to target or deplete AMLSC.
8. The method of claim 7 , wherein the antibody is a bispecific antibody that binds TIM3 and a marker set forth in Table 1.
9. The method of claim 7 , wherein the antibody is conjugated to a cytotoxic agent.
10. The method of claim 9 , wherein the cytotoxic agent is selected from the group consisting of a radioactive isotope, a chemotherapeutic agent and a toxin.
11. The method of claim 7 , wherein the contacting depletes the blood cells of AMLSC.
12. The method of claim 7 , wherein the contacting is in vivo.